Both FDA and EMA emphasize patient input in the drug development process and expect industry to consider the patient voice during regulatory decision-making. Embedding stakeholder perspectives, whether patient, consumer, or health care professionals, in strategic and tactical plans is crucial to a company’s success at all stages of the drug development continuum. Whether a company is entering a new therapeutic area, planning for launch, or managing a product maturing within marketplace, there are a variety of ways advocates can lend their perspective to anticipate and manage challenges throughout the drug lifecycle.
Our forums convene priority stakeholders so our clients can hear directly from patient, consumer, and health care professional partners about unmet needs and challenges. MK&A will develop short- and long-term strategies that address key shared interests and drive outcomes to meet your business objectives and advance mutual benefit.
To help a company maximize the benefit of convening a stakeholder forum, MK&A also offers:
Private introductory meetings with advocates and KOLs to learn about key issues and identify mutual goals
Advisory board style meeting to identify gaps along the journey, designed to gain a holistic perspective of the patient’s experience
Issue-focused advisory boards bringing together advocates, e-patients, and or multi-specialty meetings of HCPs and KOLs to understand specific issues within a disease area